Q32 Bio Inc.

QTTB
$5.80 (+ $0.30 + 5.45%)
Last updated: 2026-05-25 19:33 UTC
QTTB Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS4380831077
CUSIP438083107
Market Price5.8
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-3.49
Market Cap$39.4M
Book Value-1.5
Price to Book-2.135
BetaN/A
52w High6.37
52w Low1.34
Next Earnings DateN/A

Q32 Bio Inc. trades under ticker QTTB on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US4380831077, CUSIP 438083107.

About the Company
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Price History